NASDAQ:GLYC

GlycoMimetics - GLYC Stock Forecast, Price & News

$0.57

-0.01 (-2.14%)

(As of 09/27/2022 12:00 PM ET)

Add

Compare

Today's Range: $0.57
▼
$0.60
50-Day Range: $0.56
▼
$0.90
52-Week Range: $0.51
▼
$2.50

Volume: 1,240 shs
Average Volume: 136,981 shs
Market Capitalization: $29.96 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

GlycoMimetics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,387.3% Upside
$8.50 Price Target
Short Interest: Healthy
1.20% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.55
Upright™ Environmental Score
News Sentiment: 0.48
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.05) to ($0.82) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

291st out of 1,071 stocks

Pharmaceutical Preparations Industry

120th out of 531 stocks

3.5

Analyst's Opinion

Consensus Rating
GlycoMimetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.50, GlycoMimetics has a forecasted upside of 1,387.3% from its current price of $0.57.
Amount of Analyst Coverage
GlycoMimetics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.20% of the float of GlycoMimetics has been sold short.
Short Interest Ratio / Days to Cover
GlycoMimetics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in GlycoMimetics has recently increased by 6.08%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
GlycoMimetics does not currently pay a dividend.
Dividend Growth
GlycoMimetics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
GlycoMimetics has received a 73.56% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for GlycoMimetics is -0.55.

1.9

News and Social Media Coverage

News Sentiment
GlycoMimetics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for GlycoMimetics this week, compared to 2 articles on an average week.
Search Interest
Only 4 people have searched for GLYC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added GlycoMimetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GlycoMimetics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.00% of the stock of GlycoMimetics is held by insiders.
Percentage Held by Institutions
50.65% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for GlycoMimetics are expected to grow in the coming year, from ($1.05) to ($0.82) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of GlycoMimetics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of GlycoMimetics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
GlycoMimetics has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About GlycoMimetics (NASDAQ:GLYC) Stock

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

GLYC Stock News Headlines

September 24, 2022 | americanbankingnews.com

StockNews.com Initiates Coverage on GlycoMimetics (NASDAQ:GLYC)

September 22, 2022 | americanbankingnews.com

GlycoMimetics, Inc. (NASDAQ:GLYC) Short Interest Update

September 21, 2022 | benzinga.com

12 Health Care Stocks Moving In Tuesday's Intraday Session - bluebird bio (NASDAQ:BLUE), Apexigen (NASDAQ - Benzinga

September 16, 2022 | benzinga.com

Sickle Cell Disease Treatment Global Market to Reach $4 Billion by 2027 - Benzinga

September 14, 2022 | streetinsider.com

Form 425 Maxpro Capital Acquisiti Filed by: Apollomics Inc. - StreetInsider.com

September 9, 2022 | benzinga.com

Sickle Cell Disease Treatment Global Market Report 2022: Increase in the Number of Individuals Suffering - Benzinga

September 8, 2022 | nasdaq.com

GlycoMimetics Says Edwin Rock Joins As Chief Medical Officer - Nasdaq

September 7, 2022 | seekingalpha.com

GlycoMimetics has a new chief medical officer - Seeking Alpha

September 7, 2022 | benzinga.com

GlycoMimetics (GLYC) – GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Invest - Benzinga

September 7, 2022 | finance.yahoo.com

GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference

September 6, 2022 | finance.yahoo.com

GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer

August 9, 2022 | finance.yahoo.com

PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights - Yahoo Finance

August 9, 2022 | nasdaq.com

What Makes GlycoMimetics (GLYC) a New Buy Stock - Nasdaq

August 9, 2022 | finance.yahoo.com

What Makes GlycoMimetics (GLYC) a New Buy Stock

August 5, 2022 | nasdaq.com

Investors in Mondelez International (NASDAQ:MDLZ) have made a respectable return of 66% over the past five years - Nasdaq

August 5, 2022 | nasdaq.com

Can GlycoMimetics (NASDAQ:GLYC) Afford To Invest In Growth? - Nasdaq

August 4, 2022 | globenewswire.com

Amicus Therapeutics Announces Second Quarter 2022 Financial Results - GlobeNewswire

August 3, 2022 | finance.yahoo.com

Government of Canada helps support healthy living behaviours for Indigenous communities in British Columbia - Yahoo Finance

August 3, 2022 | finance.yahoo.com

Enteris BioPharma Manufacturing Expertise Highlighted in Drug Development & Delivery Special Feature on Outsourcing Formulation Development & Manufacturing - Yahoo Finance

August 3, 2022 | investing.com

GlycoMimetics Tops Q2 EPS by 4c By Investing.com - Investing.com

August 3, 2022 | finance.yahoo.com

GlycoMimetics (GLYC) Q2 2022 Earnings Call Transcript

August 3, 2022 | ca.investing.com

GlycoMimetics Tops Q2 EPS by 4c By Investing.com - Investing.com Canada

August 3, 2022 | benzinga.com

Recap: GlycoMimetics Q2 Earnings - Benzinga

August 3, 2022 | uk.investing.com

GlycoMimetics Tops Q2 EPS by 4c By Investing.com - Investing.com UK

August 3, 2022 | greenwichtime.com

GlycoMimetics: Q2 Earnings Snapshot - Greenwich Time

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

GLYC Company Calendar

Last Earnings: 8/03/2022
Today: 9/27/2022
Next Earnings (Estimated): 11/01/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GLYC
CUSIP: N/A
CIK: 1253689
Web: www.glycomimetics.com
Phone: (240) 243-1201
Fax: 301-738-2137
Employees: 52
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.50
High Stock Price Forecast: $13.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +599.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-63,430,000.00
Net Margins: N/A
Pretax Margin: -34,819.44%
Return on Equity: -83.03%
Return on Assets: -71.87%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.85
Quick Ratio: 6.85

Sales & Book Value

Annual Sales: $1.16 million
Price / Sales: 25.83
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.58 per share
Price / Book: 0.36

Miscellaneous

Outstanding Shares: 52,420,000
Free Float: 48,230,000
Market Cap: $29.96 million
Optionable: Optionable
Beta: 1.76

Key Executives

Mr. Harout Semerjian (Age 52)
CEO, Pres & Director
Comp: $481.96k

Mr. Brian M. Hahn (Age 48)
Sr. VP & CFO
Comp: $804.38k

Dr. John L. Magnani (Age 69)
Sr. VP of Research & Chief Scientific Officer
Comp: $803.16k

Ms. Stephanie R. Irish (Age 51)
VP of Accounting

Mr. Christian Dinneen-Long
VP, Corp. Counsel & Corp. Sec.

Mr. Armand Girard (Age 53)
Chief Bus. Officer and Sr. VP of Strategy & Corp. Devel.

Mr. Bruce Johnson
Sr. VP & Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GLYC Stock - Frequently Asked Questions

Should I buy or sell GlycoMimetics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GLYC shares.
View GLYC analyst ratings or view top-rated stocks.
What is GlycoMimetics' stock price forecast for 2022?: 2 brokerages have issued 1 year price targets for GlycoMimetics' stock. Their GLYC share price forecasts range from $4.00 to $13.00. On average, they anticipate the company's stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 1,355.5% from the stock's current price.
View analysts price targets for GLYC or view top-rated stocks among Wall Street analysts.
How have GLYC shares performed in 2022?: GlycoMimetics' stock was trading at $1.44 at the beginning of 2022. Since then, GLYC stock has decreased by 59.4% and is now trading at $0.5840.
View the best growth stocks for 2022 here.
When is GlycoMimetics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our GLYC earnings forecast.
How were GlycoMimetics' earnings last quarter?: GlycoMimetics, Inc. (NASDAQ:GLYC) released its quarterly earnings data on Wednesday, August, 3rd. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.04. The biotechnology company had revenue of $0.08 million for the quarter.

What other stocks do shareholders of GlycoMimetics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other GlycoMimetics investors own include Exelixis (EXEL), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Cidara Therapeutics (cdtx), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Spectrum Pharmaceuticals (SPPI), Coherus BioSciences (CHRS), Verastem (VSTM) and Aldeyra Therapeutics (ALDX).
What is GlycoMimetics' stock symbol?: GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."
Who are GlycoMimetics' major shareholders?: GlycoMimetics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.08%), Millennium Management LLC (0.83%), Franklin Resources Inc. (0.23%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brian M Hahn, Bvf Partners L P/Il, Daniel M Junius, John L Magnani and Patricia S Andrews.
View institutional ownership trends.
How do I buy shares of GlycoMimetics?: Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is GlycoMimetics' stock price today?: One share of GLYC stock can currently be purchased for approximately $0.58.
How much money does GlycoMimetics make?: GlycoMimetics (NASDAQ:GLYC) has a market capitalization of $30.61 million and generates $1.16 million in revenue each year. The biotechnology company earns $-63,430,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.
How can I contact GlycoMimetics?: GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The official website for the company is www.glycomimetics.com. The biotechnology company can be reached via phone at (240) 243-1201, via email at sannes@annesassociates.com, or via fax at 301-738-2137.

This page (NASDAQ:GLYC) was last updated on 9/27/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

GlycoMimetics - GLYC Stock Forecast, Price & News

GlycoMimetics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About GlycoMimetics (NASDAQ:GLYC) Stock

GLYC Stock News Headlines

GLYC Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

GLYC Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™